Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.035
Sell
RSI(14)
34.009
Neutral
STOCH(KDJ)(9,3,3)
10.590
Oversold
ATR(14)
0.106
Low Volatility
CCI(14)
-85.140
Neutral
Williams %R
98.077
Oversold
TRIX(12,20)
-0.930
Sell
StochRSI(14)
0.000
Sell
Search
Ocugen Inc
OCGNAdd to Watchlist
1.390USD
-0.070-4.79%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
434.12MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Ocugen Inc
Currency: USD Updated: 2026-05-15Key Insights
Ocugen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.57.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ocugen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ocugen Inc Highlights
StrengthsRisks
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.41M.
Fairly Valued
The company’s latest PE is -5.99, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 81.01M shares, increasing 0.03% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 1.70M shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
11.571
Target Price
+692.56%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Ocugen Inc is 6.02, ranking 292 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.53M, representing a year-over-year increase of 3.51%, while its net profit experienced a year-over-year increase of 24.93%.
Score
Financials
6.07
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.17
Operational Efficiency
2.84
Growth Potential
6.96
Shareholder Returns
7.08
Ocugen Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Ocugen Inc is 6.35, ranking 280 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.99, which is -83.52% below the recent high of -0.99 and -91.02% above the recent low of -11.44.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 128/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Ocugen Inc is 8.29, ranking 137 out of 382 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 15.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
11.571
Target Price
+692.56%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Ocugen Inc
OCGN
7
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Ocugen Inc is 6.70, ranking 183 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.73 and the support level at 1.21, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.454
Sell
MA10
1.501
Sell
MA20
1.611
Sell
MA50
1.823
Sell
MA100
1.697
Sell
MA200
1.499
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Ocugen Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 24.06%, representing a quarter-over-quarter increase of 8.77%. The largest institutional shareholder is James Simons, holding a total of 1.70M shares, representing 0.50% of shares outstanding, with 57.60% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ocugen Inc is 4.19, ranking 96 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
2.23
VaR
+7.77%
240-Day Maximum Drawdown
+43.95%
240-Day Volatility
+87.89%
Return
Best Daily Return
60 days
+29.94%
120 days
+29.94%
5 years
+29.94%
Worst Daily Return
60 days
-19.46%
120 days
-19.46%
5 years
-35.05%
Sharpe Ratio
60 days
+0.24
120 days
+0.90
5 years
+0.08
Risk Assessment
Maximum Drawdown
240 days
+43.95%
3 years
+73.92%
5 years
+97.71%
Return-to-Drawdown Ratio
240 days
+1.50
3 years
+0.66
5 years
-0.16
Skewness
240 days
+0.94
3 years
+0.96
5 years
+0.37
Volatility
Realised Volatility
240 days
+87.89%
5 years
+97.56%
Standardised True Range
240 days
+8.12%
5 years
+12.69%
Downside Risk-Adjusted Return
120 days
+141.56%
240 days
+141.56%
Maximum Daily Upside Volatility
60 days
+96.36%
Maximum Daily Downside Volatility
60 days
+73.84%
Liquidity
Average Turnover Rate
60 days
+3.12%
120 days
+2.32%
5 years
--
Turnover Deviation
20 days
+55.55%
60 days
+71.60%
120 days
+27.87%
Peer Comparison
Biotechnology & Medical Research
Ocugen Inc
OCGN
6.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
